CoChat

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer

Open access
Adeegbe, Dennis O., Liu, Yan, Lizotte, Patrick H., Kamihara, Yusuke, Aref, Amir R., Almonte, Christina, Dries, Ruben, Li, Yuyang, Liu, Shengwu, Wang, Xiaoen, Warner-Hatten, Tiquella, Castrillon, Jessica, Yuan, Guo-Cheng, Poudel-Neupane, Neermala, Zhang, Haikuo, Guerriero, Jennifer L., Han, Shiwei, Awad, Mark M., Barbie, David A., Ritz, Jerome, Jones, Simon S., Hammerman, Peter S., Bradner, James, Quayle, Steven N., Wong, Kwok-Kin · 2017 · Cancer Discovery
Cited by 149

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Effective therapies for non–small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways. It is now clear that therapeutic agents with potential to impact the tumor immune microenvironment potentiate immune-orchestrated therapeutic benefit. Herein, we evaluated the immunoregulatory properties of histone deacetylase (HDAC) and bromodomain inhibitors, two classes of drugs that modulate the epigenome, with a focus on key cell subsets that are engaged in an immune response. By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells. The bromodomain inhibitor JQ1 attenuated CD4+FOXP3+ T regulatory cell suppressive function and synergized with ricolinostat to facilitate immune-mediated tumor growth arrest, leading to prolonged survival of mice with lung adenocarcinomas. Collectively, our findings highlight the immunomodulatory effects of two epigenetic modifiers that, together, promote T cell–mediated antitumor immunity and demonstrate their therapeutic potential for treatment of NSCLC. Significance: Selective inhibition of HDACs and bromodomain proteins modulates tumor-associated immune cells in a manner that favors improved T-cell function and reduced inhibitory cellular mechanisms. These effects facilitated robust antitumor responses in tumor-bearing mice, demonstrating the therapeutic potential of combining these epigenetic modulators for the treatment of NSCLC. Cancer Discov; 7(8); 852–67. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 783

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-16-1020

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 149

Metadata

Authors
Adeegbe, D. O., Liu, Y., Lizotte, P. H., Kamihara, Y., Aref, A. R., Almonte, C., Dries, R., Li, Y., Liu, S., Wang, X., Warner-Hatten, T., Castrillon, J., Yuan, G.-C., Poudel-Neupane, N., Zhang, H., Guerriero, J. L., Han, S., Awad, M. M., Barbie, D. A., Ritz, J., Jones, S. S., Hammerman, P. S., Bradner, J., Quayle, S. N., & Wong, K.-K.
Venue
Cancer Discovery
Published
2017-08-01
Volume
7
Issue
8
Pages
852-867
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2606377102
Cited by
149
References
14
FWCI
6.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.